

## Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.tandfonline.com/loi/Incn20>

### Synthesis and Evaluation of Antimicrobial Activity of Some Pyrimidine Glycosides

H. A. El-Sayed <sup>a</sup>, A. H. Moustafa <sup>a</sup>, A. Z. Haikal <sup>a</sup>, I. M. Abdou <sup>b</sup> & E. S. H. El-Ashry <sup>c</sup>

<sup>a</sup> Department of Chemistry, Faculty of Science, Zagazig Univeristy, Zagazig, Egypt

<sup>b</sup> Department of Chemistry, Faculty of Science, United Arab Emirates University, United Arab Emirates

<sup>c</sup> Department of Chemistry, Faculty of Science, Alexandria University, Alexandria, Egypt

Version of record first published: 18 Aug 2008.

To cite this article: H. A. El-Sayed, A. H. Moustafa, A. Z. Haikal, I. M. Abdou & E. S. H. El-Ashry (2008): Synthesis and Evaluation of Antimicrobial Activity of Some Pyrimidine Glycosides, *Nucleosides, Nucleotides and Nucleic Acids*, 27:9, 1061-1071

To link to this article: <http://dx.doi.org/10.1080/15257770802271805>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.tandfonline.com/page/terms-and-conditions>

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae, and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand, or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

## SYNTHESIS AND EVALUATION OF ANTIMICROBIAL ACTIVITY OF SOME PYRIMIDINE GLYCOSIDES

H. A. El-Sayed,<sup>1</sup> A. H. Moustafa,<sup>1</sup> A. Z. Haikal,<sup>1</sup> I. M. Abdou,<sup>2</sup> and E. S. H. El-Ashry<sup>3</sup>

<sup>1</sup>Department of Chemistry, Faculty of Science, Zagazig Univeristy, Zagazig, Egypt

<sup>2</sup>Department of Chemistry, Faculty of Science, United Arab Emirates University, United Arab Emirates

<sup>3</sup>Department of Chemistry, Faculty of Science, Alexandria University, Alexandria, Egypt

□ Reaction of ethyl 4-thioxo-3,4-dihydropyrimidine-5-carboxylate derivatives **1a,b** and ethyl 4-oxo-3,4-dihydropyrimidine-5-carboxylate **1c** with 2,3,4,6-tetra-O-acetyl- $\alpha$ -D-glucopyranosyl bromide in KOH or TEA afforded ethyl 2-aryl-4-(2',3',4',6'-tetra-O-acetyl- $\beta$ -D-glucopyranosylthio or/ oxy)-6-methylpyrimidine-5-carboxylate **6a-c**. The glucosides **6a** and **6b** were obtained by the reaction of **1a** and **1b** with peracetylated glucose<sup>3</sup> under MW irradiation. Mercuration of **1a** followed by reaction with acetobromoglucose gave the same product **6a**. The reaction of **1a-c** with peracetylated ribose **4** under MW irradiation gave ethyl 2-aryl-4-(2',3',5'-tri-O-acetyl- $\beta$ -D-ribofuranosylthio)-6-methylpyrimidine-5-carboxylate **8a-c**. The deprotection of **6a-c** and **8a-c** in the presence of methanol and TEA/H<sub>2</sub>O afforded the deprotected products **7a-c** and **9a-c**. The structure were confirmed by using <sup>1</sup>H and <sup>13</sup>CNMR spectra. Selected members of these compounds were screened for antimicrobial activity.

**Keywords** Pyrimidin-4-one or/thione; pyrimidine glycosides and/ribosides; antimicrobial activity

## INTRODUCTION

Pyrimidines, being an integral part of DNA and RNA, play an essential role in several biological processes and have considerable chemical and pharmacological importance. The pyrimidine ring can be found in antiviral nucleosides, antibiotics, antibacterials, antitumor, cardiovascular as well as agrochemical, veterinary products and antimycobacterial agents.<sup>[1–6]</sup> Some pyrimidine derivatives exhibit potent nanomolar activities against GSK-3 $\beta$

Received 7 April 2008; accepted 22 May 2008.


Address correspondence to A. H. Moustafa, Department of Chemistry, Faculty of Science, Zagazig Univeristy, Zagazig, Egypt. E-mail: ah\_hu\_mostafa@yahoo.com

kinase as well as in an NF- $\kappa$ B reporter gene assay,<sup>[7]</sup> and anticancer activity against the MCF-7 cell line.<sup>[8]</sup> There are pyrimidine acyclic nucleosides that act as moderate viral replication inhibitors against HBV.<sup>[9]</sup>

Glycosylthio-heterocycles have attracted much attention because of their abilities to function as biological inhibitors,<sup>[10–17]</sup> inducers, and ligands<sup>[18]</sup> for affinity of chromatography of carbohydrate-process enzymes and proteins. For these reasons we synthesized several pyrimidine glycosides for evaluation of their biological activity.

## RESULTS AND DISCUSSION


We report in this work the results of our investigation into the utility of the reaction of previous reported pyrimidine<sup>[19,20]</sup> with  $\alpha$ -halo and peracetylated sugars, for the synthesis of some glucosides and ribosides. Glucosides **6a** and **6b** could be obtained by the reaction of ethyl 2-aryl-4-mercapto-6-methyl-pyrimidine-5-carboxylate (**1a**) and (**1b**) with 2,3,4,6-tetra-*O*-acetyl- $\alpha$ -D-glucopyranosyl bromide (**2**) in the presence of aqueous potassium hydroxide<sup>[4]</sup> in 50 and 69% yields, respectively. The same glucosides **6a** and **6b** could be obtained in better yields by MW irradiation of **1a** and **1b** with peracetylated glucose (**3**) for 30 seconds using silica gel as a solid support.<sup>[21]</sup> On the other hand, glucoside **6a** was obtained in 15% yield by heating chloromercuric salt **5a** of **1a** with **2** in dry xylene at reflux (Scheme 1).



SCHEME 1

The structure of **6a** and **6b** were confirmed by using IR, UV,  $^1\text{H}$ , and  $^{13}\text{C}$  NMR spectra. The  $^1\text{H}$  NMR spectra of **6a** and **6b** exhibited doublets at  $\delta$  6.22 and 6.40 with ( $J_{1',2'} = 8.00$  and 8.32 Hz), respectively, for the H-1' protons characteristic for  $\beta$ -configuration. The  $^{13}\text{C}$  NMR spectra revealed the absence of signals for (C = S) group, the presence of signals at  $\delta$  165.8 and 167.0 for C-4 atoms, and signals at  $\delta$  79.1 and 79.9 for the anomeric carbons, respectively.

Glucoside **6c** was obtained by the reaction of ethyl 2-(4-chlorophenyl)-4-oxo-6-methyl-3,4-dihydropyrimidine-5-carboxylate (**1c**) with glucosyl bromide **2** at room temperature in presence of triethylamine.<sup>[22]</sup> On the other hand, the same glucoside **6c** was obtained in 53% yield in the presence of acetone/DMF and potassium carbonate (Scheme 1). The  $^1\text{H}$  NMR spectrum of **6c** showed the singlets at  $\delta$  1.89, 2.00, 2.01, and 2.04 characteristic for the acetoxy groups of the sugar and a doublet at  $\delta$  6.21 ( $J_{1',2'} = 7.78$  Hz) for the H-1' proton which is characteristic for the  $\beta$ -configuration. The  $^{13}\text{C}$  NMR spectrum of compound **6c** showed four singlets at  $\delta$  20.4, 20.5, 20.9, and 22.6 corresponding to the four acetoxy methyl groups and also at  $\delta$  94.0 consistent with the anomeric carbon. The IR spectrum of **6c** showed the absence of an amide carbonyl band which indicates the formation of the *O*-glycoside and not the *N*-glycoside. Treatment of pyrimidines **1a** and **1b** with peracetylated ribose (**4**) under MW irradiation for 30 seconds using silica gel as a solid support<sup>[21]</sup> gave the corresponding ribosides **8a** and **8b** (Scheme 2).



SCHEME 2

The  $^1\text{H}$  NMR spectra of **8a** and **8b** showed doublets at  $\delta$  6.46 and 6.25, respectively, characteristic for the anomeric protons. The  $^{13}\text{C}$  NMR spectra of **8a** and **8b** showed the absence of C=S group and the presence of signals at  $\delta$  161.0 for C-4 and the presence of the anomeric carbons at  $\delta$  84.0 and 84.8, respectively.

Riboside **8c** was obtained by the reaction of ethyl 2-(4-chlorophenyl)-6-methyl-4-oxo-3,4-dihydropyrimidine-5-carboxylate (**1c**) with peracetylated

ribose (**4**) under MW irradiation for 30 seconds using silica gel as a solid support.<sup>[21]</sup> (See Scheme 2.) The <sup>1</sup>H NMR spectrum of **8c** showed three singlets at  $\delta$  1.86, 2.06, and 2.12 for three acetoxy groups and a doublet at  $\delta$  6.28 characteristic for the anomeric proton. The IR spectrum of **8c** showed the absence of an amide carbonyl band which indicates the formation of the *O*-glycoside and not the *N*-glycoside.

The deprotected glucosides **7a–c** and ribosides **9a–c** were obtained by treatment of the acetylated compounds **6a–c** and **8a–c**, respectively, and the reaction mixture was stirred overnight at room temperature. The structures of these products were confirmed by their spectral data (IR, <sup>1</sup>H and <sup>13</sup>C NMR). The <sup>1</sup>H NMR spectra revealed the disappearance of the acetoxy proton signals and the appearance of OH proton signals which were exchangeable with D<sub>2</sub>O. The IR spectra showed absorption bands at 3381–3434 cm<sup>−1</sup> for OH groups.

In summary, the pyrimidine glycosides were synthesized by reaction of substituted pyrimidines with glucosyl bromide (**2**), peracetylated glucose (**3**) and peracetylated ribose (**4**), respectively.

## ANTIMICROBIAL ACTIVITY

Glucosides **7a–c** and ribosides **8b** and **9a** were evaluated for antibacterial activity against Gram (−ve) bacteria (*Pseudomonas aeruginosa*) and Gram (+ve) bacteria (*Staphylococcus aureus* and *Bacillus subtilis*) using a cup plate agar diffusion method.<sup>[24]</sup> Ampicillin was used as a reference to evaluate the potency of tested compounds. Riboside **8b** showed higher antibacterial activity than the standard drug (ampicillin). Glucoside **7a** and riboside **9a** did not show any activity against tested micro-organisms. Glucosides **7b** and **7c** showed higher activity against Gram (+ve) bacteria than the standard drug but were inactive against Gram (−ve) bacteria. The results of the biological activities encourage further work on such a ring system.

**TABLE 1** Antimicrobial activity of tested compounds

Compound No.	<i>P. aeruginosa</i>	<i>S. aureus</i>	<i>B. subtilis</i>
<b>7a</b>	—	—	—
<b>7b</b>	—	10	13
<b>7c</b>	—	8	20
<b>8b</b>	25	9	11
<b>9a</b>	—	—	—
Ampicillin	23	7	6

Inhibition zones (mm), minimum inhibitory concentration (μg/mL).

## EXPERIMENTAL

All melting points are uncorrected and were measured using an Electro thermal IA 9100 apparatus. TLC was performed on Merck Silica Gel 60F<sub>254</sub> with detection by UV light and by the charring with H<sub>2</sub>SO<sub>4</sub>; IR spectra (KBr disc) were recorded on a Pye Unicam Sp-3-300 or a Shimadzu FTIR 8101 PC infrared spectrophotometer. The UV. Spectra were recorded by UV-160A, UV-visible recording spectrometer Shimadzu using DMSO (dimethylsulphoxid) as a solvent. The <sup>1</sup>H and <sup>13</sup>C NMR spectra were determined with JEOL-JNM-LA 200, 300, 400, or 500 MHz spectrometers. The chemical shifts are expressed on the  $\delta$  (ppm) scale using TMS as the standard. Elemental analyses determined on a Perkin Elmer 240 (microanalysis).

### General Methods for Preparation of Glucosides and Ribosides

#### *Method A*

To a solution of pyrimidinethione **1a** and **1b** (0.01 mol) in aqueous KOH [0.01 mol in distilled water (6 mL)] was added a solution of glucosyl bromide **2** (0.011 mol) in acetone (30 mL); the reaction mixture was stirred at room temperature for 5 hours and the reaction followed by TLC till the reaction was finished, the reaction mixture was evaporated and the residue was washed with distilled water to remove potassium bromide formed. The product was dried and crystallized from an appropriate solvent.

#### *Method B*

A mixture of pyrimidin-4-one or/thione **1a-c** (0.001 mol) and (0.001 mol) of peracetylated glucose (3) or ribose (4), respectively, were dissolved in a mixture of methylene chloride/methanol (80/20) then 1 g of silica gel (200–400 mesh) was added, the solvent was removed by evaporation, the dried residue was transferred into a glass beaker and irradiated for (0.5–3 minutes) in a domestic microwave oven. The product was extracted with methylene chloride, decolorized with charcoal and crystallized from an appropriate solvent or chromatographed on a silica gel column.

#### *Method C*

To a solution of glucosyl bromide **2** (0.011 mol) in dry xylene a solution of chloromercuric salt (0.01 mol) of the pyrimidinethione **1a** in dry xylene was added. The reaction mixture was refluxed, and followed by TLC till all starting material was consumed (4 hours), then the solvent was evaporated under reduced pressure and the residue was extracted by chloroform, the chloroform evaporated and the residue was crystallized from ethanol.

**Ethyl 2-phenyl-4-(2',3',4',6'-tetra-*O*-acetyl- $\beta$ -D-glucopyranosylthio)-6-methylpyrimidine-5-carboxylate (6a).** Method A: 50% yield; method B: 67% yield; method C: 15% yield, as colorless crystals from ethanol; m.p. 178–180°C;  $R_f$  = 0.42 (eluent:  $\text{CHCl}_3/\text{MeOH}$ , 9.9 : 0.1); UV  $\lambda_{\text{max}}$ . 302.1 nm; IR (KBr) 1760  $\text{cm}^{-1}$ , 1731  $\text{cm}^{-1}$  (C=O, acetoxy) and 1701  $\text{cm}^{-1}$  (C=O, ester);  $^1\text{H}$  NMR spectrum (300 MHz,  $\text{DMSO-d}_6$ )  $\delta$  1.34 (t, 3 H,  $J$  = 7.60 Hz  $\text{CH}_3\text{CH}_2$ ), 1.94, 1.98, 1.99 and 2.10 (4s, 12 H, 4  $\text{CH}_3\text{CO}$ ), 2.61 (s, 3 H,  $\text{CH}_3$ -6), 3.98 (m, 2 H, H-5' and H-6''), 4.38 (m, 3 H, H-6' and 2 H for  $\text{CH}_3\text{CH}_2$ ), 4.90 (t, 1 H,  $J$  = 8.10 Hz, H-4'), 5.13 (t, 1 H,  $J$  = 8.05 Hz, H-2'), 5.68 (t, 1 H,  $J$  = 8.10 Hz, H-3'), 6.22 (d, 1 H,  $J_{1',2'}$  = 8.00 Hz, H-1') and 7.57–8.50 (m, 5 H, Ar-H).  $^{13}\text{C}$  NMR (300 MHz,  $\text{DMSO-d}_6$ )  $\delta$  13.7, 20.1, 20.1, 20.2, 20.2 and 23.6 (6  $\text{CH}_3$ ), 61.9 ( $\text{CH}_3\text{CH}_2$ ), 61.9 (C-6'), 68.3 (C-4'), 68.9 (C-3'), 72.9 (C-2'), 74.9 (C-5'), 79.1 (C-1'), 128.6, 128.7, 129.0, 131.7, 135.6, 161.8, 164.8, 165.8, 165.9, 169.1, 169.2, 169.4 and 169.6 (Ar-C, 2 C=N and 5 acetyl C=O). Anal. Calcd for  $\text{C}_{28}\text{H}_{32}\text{N}_2\text{O}_{11}\text{S}$  (604.63): C, 57.60; H, 5.46; N, 4.63. Found: C, 57.43; H, 5.62; N, 4.63.

**Ethyl 2-(4-chlorophenyl)-4-(2',3',4',6'-tetra-*O*-acetyl- $\beta$ -D-glucopyranosylthio)-6-methylpyrimidine-5-carboxylate (6b).** Method A: 69% yield; method B: 70% yield, as colorless crystals from ethanol; m.p. 150–152°C;  $R_f$  = 0.38 (eluent:  $\text{CHCl}_3/\text{MeOH}$ ; 9.9 : 0.1); UV  $\lambda_{\text{max}}$ . 305 and 223 nm;  $^1\text{H}$  NMR spectrum (500 MHz,  $\text{DMSO-d}_6$ )  $\delta$  1.30 (t, 3 H,  $J$  = 7.60 Hz,  $\text{CH}_3\text{CH}_2$ ), 1.85, 1.95, 2.00, and 2.50 (4s, 12 H, 4  $\text{CH}_3\text{CO}$ ), 2.63 (s, 3 H,  $\text{CH}_3$ -6), 3.95 (m, 2 H, H-5' and H-6''), 4.4 (m, 3 H, H-6' and 2 H,  $\text{CH}_3\text{CH}_2$ ), 4.90 (t, 1 H,  $J$  = 8.6 Hz, H-4'), 5.05 (t, 1 H,  $J$  = 8.3 Hz, H-2'), 5.65 (t, 1 H,  $J$  = 8.65 Hz, H-3'), 6.25 (d, 1 H,  $J_{1',2'}$  = 8.3 Hz, H-1'), 7.60 (d, 2 H,  $J$  = 9.6 Hz, Ar-H) and 8.55 (d, 2 H,  $J$  = 9.6 Hz, Ar-H);  $^{13}\text{C}$  NMR (500 MHz,  $\text{DMSO-d}_6$ )  $\delta$  14.6, 20.7, 21.1, 21.2, 24.7 and 30.4 (6  $\text{CH}_3$ ), 62.8 ( $\text{CH}_3\text{CH}_2$ ), 62.9 (C-6'), 69.2 (C-4'), 69.7 (C-3'), 73.8 (C-2'), 75.8 (C-5'), 79.9 (C-1'), 122.0, 129.7, 131.4, 135.4, 137.6, 161.8, 165.7, 167.0, 167.1, 170.1, 170.2, 170.4 and 170.5 (Ar-C, 2 C=N and 5 acetyl C=O). Anal. Calcd for  $\text{C}_{28}\text{H}_{31}\text{ClN}_2\text{O}_{11}\text{S}$  (638.07): C, 52.62; H, 4.89; N, 4.38. Found: C, 52.45; H, 4.92; N, 4.24.

**Ethyl 2-(4-chlorophenyl)-4-(2',3',4',6'-tetra-*O*-acetyl- $\beta$ -D-glucopyranosyloxy)-6-methylpyrimidine-5-carboxylate (6c).**

#### Method D

Glucosyl bromide **2** (0.0011 mol) was added to a solution of ethyl 4-oxo-3,4-dihydropyrimidine-5-carboxylate **1c** (0.001 mol) in dry acetonitrile (5 mL); triethylamine (0.2 mL, 0.0014 mol) was added, the reaction mixture was stirred overnight at room temperature, then cooled in an ice bath and acidified with acetic acid. The precipitate was collected by filtration, dried and finally crystallized from ethanol.

#### Method E

A mixture of ethyl 4-oxo-3,4-dihydropyrimidine-5-carboxylate **1c** (0.001 mol) and 0.001 mol potassium carbonate was stirred in acetone or a mixture

of acetone/DMF (15 mL) for 1 hour, then (0.0011 mol) glucosyl bromide **2** was added, the stirring was continued overnight then the mixture was heated at reflux for 3 hours, filtered, the solvent was evaporated under vacuum, and the residue was crystallized from ethanol.

**Method D:** 40% yield; method E : 53% yield, as colorless crystals from ethanol; m.p. 156–157°C;  $R_f = 0.47$  (eluent:  $\text{CH}_2\text{Cl}_2/\text{MeOH}$ ; 9.9 : 0.1), UV  $\lambda_{\text{max}}$  271 and 242.5 nm; IR (KBr) 1758 and 1731  $\text{cm}^{-1}$  (C=O, ester);  $^1\text{H}$  NMR spectrum (400 MHz,  $\text{CDCl}_3$ )  $\delta$  1.37 (t, 3 H,  $J = 7.12$  Hz,  $\text{CH}_3\text{CH}_2$ ), 1.89, 2.00, 2.01 and 2.04 (4s, 12 H, 4  $\text{CH}_3\text{CO}$ ), 2.57 (s, 1 H,  $\text{CH}_3$ -6), 4.00 (m, 1 H, H-5'), 4.14 (dd, 1H,  $J_{5',6''} = 2.10$ ,  $J_{6',6''} = 12.3$  Hz, H-6''), 4.22 (dd, 1 H,  $J_{5',6'} = 5.69$ ,  $J_{6',6''} = 12.3$  Hz, H-6'), 4.39 (q, 2 H,  $J = 7.12$  Hz,  $\text{CH}_3\text{CH}_2$ ), 5.15 (t, 1 H,  $J_{3',4'} = 8.97$ ,  $J_{4',5'} = 9.13$  Hz, H-4'), 5.31 (t, 1 H,  $J_{1',2'} = 7.7$ ,  $J_{2',3'} = 9.22$  Hz, H-2'), 5.36 (t, 1 H,  $J_{2',3'} = 9.2$ ,  $J_{3',4'} = 8.78$  Hz, H-3'), 6.21 (d, 1 H,  $J_{1',2'} = 7.78$  Hz, H-1'), 7.39 (d, 2 H,  $J = 8.53$  Hz, Ar-H), 8.33 (d, 2 H,  $J = 8.53$  Hz, Ar-H);  $^{13}\text{C}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  14.0, 20.4, 20.5, 20.5, 22.6 and 29.6 (6  $\text{CH}_3$ ), 62.0 ( $\text{CH}_3\text{CH}_2$ ), 62.1 (C-6'), 68.5 (C-4'), 70.3 (C-3'), 72.7 (C-2'), 72.9 (C-5'), 94.0 (C-1'), 128.8, 128.9, 129.0, 135.0, 137.7, 162.4, 164.6, 164.9, 167.5, 169.0, 169.3, 170.0 and 170.4 (Ar-C, 2 C=N and 5 acetyl C=O). Anal. Calcd for  $\text{C}_{28}\text{H}_{31}\text{Cl N}_2\text{O}_{12}$  (622.16): C, 53.98; H, 5.02; N, 4.50. Found: C, 53.76; H, 5.12; N, 4.57.

**Ethyl 2-phenyl-4-( $\beta$ -D-glucopyranosylthio)-6-methylpyrimidine-5-carboxylate (7a).** *General method for deacetylation:* Triethylamine (1 mL) was added to a solution of glucosides **6a–c** or ribosides **8a–c** (0.001 mol) in (10 mL MeOH and 3 drops of water). The mixture was stirred overnight at room temperature, evaporated under reduced pressure and the residue was co-evaporated with MeOH until the triethylamine was removed. The residue was crystallized from ethanol/water to give colorless crystals; 85% yield; m.p. 190–191°C;  $R_f = 0.32$  (eluent:  $\text{CH}_2\text{Cl}_2/\text{MeOH}$ ; 9.6 : 0.4); IR (KBr) 3411  $\text{cm}^{-1}$  (broad, 4 OH) and 1723  $\text{cm}^{-1}$  (CO, ester);  $^1\text{H}$  NMR spectrum (300 MHz,  $\text{DMSO}-d_6$ )  $\delta$  1.34 (t, 3 H,  $J = 6.93$  Hz,  $\text{CH}_3\text{CH}_2$ ), 2.56 (s, 3 H,  $\text{CH}_3$ -6), 3.12–3.50 (m, 6 H, H-6', H-6'', H-5', H-4', H-3' and H-2'), 4.38 (q, 2 H,  $J = 6.93$  Hz, for  $\text{CH}_3\text{CH}_2$ ), 4.51 (t, 1 H,  $J = 3.32$  Hz, OH-6'), 5.08 (d, 1 H,  $J = 4.36$  Hz, OH-4'), 5.23 (d, 1 H,  $J = 3.84$  Hz, OH-3'), 5.47 (d, 1 H,  $J = 4.70$  Hz, OH-2'), 5.63 (d, 1 H,  $J_{1',2'} = 7.86$  Hz, H-1'), 7.55–8.39 (m, 5 H, Ar-H).  $^{13}\text{C}$ -NMR (300 MHz,  $\text{DMSO}-d_6$ )  $\delta$  13.9 and 23.4 (2  $\text{CH}_3$ ), 60.6 ( $\text{CH}_3\text{CH}_2$ ), 61.9 (C-6'), 69.0 (C-2'), 63 (C-2'), 71.8 (C-3'), 78.6 (C-4'), 81.7 (C-5'), 82.8 (C-1'), 121.4, 128.8, 131.6, 135.2, 136.2, 161.9, 164.7, 165.4 and 167.3 (Ar-C, 2 C = N and C=O). Anal. Calcd for  $\text{C}_{20}\text{H}_{24}\text{N}_2\text{O}_7\text{S}$  (436.48): C, 55.04; H, 5.70; N, 6.40. Found: C, 54.90; H, 6.03; N, 6.27.

**Ethyl 2-(4-chlorophenyl)-4-( $\beta$ -D-glucopyranosylthio)-6-methylpyrimidine-5-carboxylate (7b).** As for **7a**; crystallized from ethanol/water to give colorless crystals; 86% yield; m.p. 194–196°C;  $R_f = 0.3$  (eluent:  $\text{CH}_2\text{Cl}_2/\text{MeOH}$ ; 9.6 : 0.4); IR (KBr) 3434  $\text{cm}^{-1}$  (broad, 4 OH) and 1717  $\text{cm}^{-1}$  (CO, ester);  $^1\text{H}$



NMR spectrum (300 MHz, DMSO- $d_6$ )  $\delta$  1.33 (t, 3 H,  $J = 7.0$  Hz,  $\text{CH}_3\text{CH}_2$ ), 2.56 (s, 3 H,  $\text{CH}_3$ -6), 3.13–3.64 (m, 6 H, H-6', H-6'', H-5', H-4', H-3' and H-2'), 4.38 (q, 2 H,  $J = 7.0$  Hz,  $\text{CH}_3\text{CH}_2$ ), 4.5 (t, 1 H,  $J = 3.56$  Hz, OH-6'), 5.09 (d, 1 H,  $J = 4.34$  Hz, OH-4'), 5.22 (d, 1 H,  $J = 4.20$  Hz, OH-3'), 5.47 (d, 1 H,  $J = 4.96$  Hz, OH-2'), 5.57 (d, 1 H,  $J_{1',2'} = 7.79$  Hz, H-1'), 7.59 (d, 2 H,  $J = 8.3$  Hz, Ar-H) 8.38 (d, 2 H,  $J = 8.3$  Hz, Ar-H);  $^{13}\text{C}$ -NMR (300 MHz, DMSO- $d_6$ )  $\delta$  13.9 and 23.3 (2  $\text{CH}_3$ ), 60.7 ( $\text{CH}_3\text{CH}_2$ ), 62.0 (C-6'), 69.6 (C-2'), 71.6 (C-3'), 78.5 (C-4'), 81.8 (C-5'), 82.8 (C-1'), 121.5, 128.9, 130.2, 135.0, 136.5, 160.9, 164.83, 165.3 and 167.6 (Ar-C, 2 C=N and C=O). Anal. Calcd for  $\text{C}_{20}\text{H}_{23}\text{ClN}_2\text{O}_7\text{S}$  (470.92): C, 56.17; H, 6.17; N, 4.9. Found: C, 56.10; H, 6.40; N, 5.07.

**Ethyl 2-(4-chlorophenyl)-4-( $\beta$ -D-glucopyranosyloxy)-6-methylpyrimidin-5-carboxylate (7c).** As for 7a; crystallized from ethanol/water to give colorless crystals; 85% yield; m.p. 180–182°C;  $R_f = 0.42$  (eluent:  $\text{CH}_2\text{Cl}_2/\text{MeOH}$ ; 9.1 : 0.9);  $^1\text{H}$  NMR spectrum (200 MHz, DMSO- $d_6/\text{D}_2\text{O}$ )  $\delta$  1.39 (t, 3 H,  $J = 7.2$  Hz,  $\text{CH}_3\text{CH}_2$ ), 2.58 (s, 3 H,  $\text{CH}_3$ -6), 3.20–3.61 (m, 6 H, H-6', H-6'', H-5', H-4', H-3' and H-2'), 4.42 (q, 2 H,  $J = 7.2$  Hz,  $\text{CH}_3\text{CH}_2$ ), 6.11 (d, 1 H,  $J_{1',2'} = 7.2$  Hz, H-1'), 7.67 (d, 2 H,  $J = 8.8$  Hz, Ar-H), 8.46 (d, 2 H,  $J = 8.8$  Hz, Ar-H). Anal. Calcd for  $\text{C}_{20}\text{H}_{23}\text{Cl N}_2\text{O}_8$  (454.11): C, 52.81; H, 5.10; N, 6.16. Found: C, 53.10; H, 5.22; N, 5.86.

**Ethyl 2-phenyl-4-(2',3',5'-tri-*O*-acetyl- $\beta$ -D-ribofuranosylthio)-6-methylpyrimidine-5-carboxylate (8a).** Method B: 82% yield, as Colorless crystals from methanol; m.p. 79–80°C;  $R_f = 0.43$  (eluent:  $\text{CH}_2\text{Cl}_2/\text{MeOH}$ ; 9.8 : 0.2); UV  $\lambda_{\text{max}}$  298 nm;  $^1\text{H}$  NMR spectrum (200 MHz,  $\text{CDCl}_3$ )  $\delta$  1.43 (t, 3 H,  $J = 5.20$  Hz,  $\text{CH}_3\text{CH}_2$ ), 2.06, 2.07 and 2.15 (3s, 9 H, 3  $\text{CH}_3\text{CO}$ ), 2.70 (s, 3 H,  $\text{CH}_3$ -6), 4.11 (dd, 1 H,  $J_{4',5'} = 3.4$ ,  $J_{5',5''} = 11.6$  Hz, H-5'), 4.16 (dd, 1 H,  $J_{4',5''} = 3.6$ ,  $J_{5',5''} = 11.6$  Hz, H-5''), 4.42 (m, 3 H,  $\text{CH}_3\text{CH}_2$  and H-4'), 5.54 (dd, 1 H,  $J_{2',3'} = 2.7$ ,  $J_{3',4'} = 6.6$  Hz, H-3'), 5.63 (dd, 1 H,  $J_{1',2'} = 2.6$ ,  $J_{2',3'} = 2.80$  Hz, H-2'), 6.46 (d, 1 H,  $J_{1',2'} = 2.4$  Hz, H-1'), 7.45–8.40 (m, 5 H, Ar-H);  $^{13}\text{C}$  NMR (200 MHz,  $\text{CDCl}_3$ )  $\delta$  13.0, 19.4, 19.4, 19.7 and 23.2 (5  $\text{CH}_3$ ), 61.1 ( $\text{CH}_3\text{CH}_2$ ), 61.1 (C-5'), 69.0 (C-3'), 74.4 (C-2'), 77.9 (C-4'), 84.0 (C-1'), 127.3, 127.6, 127.9, 128.1, 131.3, 134.8, 160.7, 161.0, 164.1, 168.3, 168.5 and 169.0 (Ar-C, 2 C=N and 4 acetyl C=O). Anal. Calcd for  $\text{C}_{25}\text{H}_{28}\text{N}_2\text{O}_9\text{S}$  (532.38): C, 56.38; H, 5.30; N, 5.26. Found: C, 56.42; H, 5.21; N, 5.33.

**Ethyl 2-(4-chlorophenyl)-4-(2',3',5'-tri-*O*-acetyl- $\beta$ -D-ribofuranosylthio)-6-methylpyrimidine-5-carboxylate (8b).** Method B: 79% yield, as colorless crystals from methanol; m.p. 129–130°C;  $R_f = 0.38$  (eluent:  $\text{CH}_2\text{Cl}_2/\text{MeOH}$ ; 9.8: 0.2); UV  $\lambda_{\text{max}}$  318 and 269.5 nm;  $^1\text{H}$  NMR spectrum (200 MHz, DMSO- $d_6$ )  $\delta$  1.40 (t, 3 H,  $J = 7.5$  Hz,  $\text{CH}_3\text{CH}_2$ ), 2.10, 2.15 and 2.23 (3s, 9 H, 3  $\text{CH}_3\text{CO}$ ), 2.69 (s, 3 H,  $\text{CH}_3$ -6), 4.10, (dd, 1 H,  $J_{4',5'} = 4.8$ ,  $J_{5',5''} = 11.2$  Hz, H-5'), 4.17 (dd, 1 H,  $J_{4',5''} = 4.6$ ,  $J_{5',5''} = 11.2$  Hz, H-5''), 4.50 (m, 3 H,  $\text{CH}_3\text{CH}_2$  and H-4'), 5.48 (dd, 1 H,  $J_{2',3'} = 3.1$ ,  $J_{3',4'} = 6.8$  Hz, H-3'), 5.59 (dd, 1 H,  $J_{1',2'} = 2.4$ ,  $J_{2',3'} = 3.0$  Hz, H-2'), 6.44 (d, 1 H, H-1',  $J_{1',2'} = 2.4$  Hz), 7.60 (d, 2

H, J = 8.4 Hz, Ar-H), 8.35 (d, 2 H, J = 8.4 Hz, Ar-H);  $^{13}\text{C}$  NMR (200 MHz, DMSO- $d_6$ )  $\delta$  13.8, 20.2, 20.5, 23.9 and 24.0 (5  $\text{CH}_3$ ), 62.0 ( $\text{CH}_3\text{CH}_2$ ), 62.1 (C-5'), 69.9 (C-3'), 75.1 (C-2'), 78.9 (C-4'), 84.8 (C-1'), 128.9, 129.0, 129.5, 129.9, 134.6, 136.8, 160.7, 161.0, 164.9, 166.0, 169.4 and 169.8 (Ar-C, 2 C=N and 4 acetyl C=O). Anal. Calcd for  $\text{C}_{25}\text{H}_{27}\text{Cl N}_2\text{O}_9\text{S}$  (566.11): C, 52.96; H, 4.80; N, 4.94. Found: C, 52.93; H, 4.74; N, 4.86.

**Ethyl 2-(4-chlorophenyl)-4-(2',3',5'-tri-O-acetyl- $\beta$ -D-ribofuranosyloxy)-6-methylpyrimidine-5-carboxylate (8c).** Method B: 08% yield, as colorless crystals chromatographed by using  $\text{CH}_2\text{Cl}_2$  as eluent; m.p. 96–97°C;  $R_f$  = 0.3 (eluent:  $\text{CH}_2\text{Cl}_2$ /MeOH; 9.8 : 0.2); IR (KBr)  $1735\text{ cm}^{-1}$  (C=O, ester);  $^1\text{H}$  NMR spectrum (300 MHz; DMSO- $d_6$ )  $\delta$  1.40 (t, 3 H, J = 7.5 Hz,  $\text{CH}_3\text{CH}_2$ ), 1.86, 2.06 and 2.12 (3s, 9 H, 3  $\text{CH}_3\text{CO}$ ), 2.5 (s, 3 H,  $\text{CH}_3$ -6), 4.12 (m, 2 H, H-5', 5''), 4.38 (m, 3 H,  $\text{CH}_3\text{CH}_2$  and H-4'), 5.46 (m, 2 H, H-2' and H-3'), 6.28 (d, 1 H,  $J_{1',2'} = 3.4\text{ Hz}$ , H-1'), 7.63 (d, 2 H, J = 6.9 Hz, Ar-H), 8.04 (d, 2 H, J = 6.9 Hz, Ar-H). Anal. Calcd for  $\text{C}_{25}\text{H}_{27}\text{Cl N}_2\text{O}_{10}$  (550.14) : C, 54.50; H, 4.94; N, 5.08. Found: C, 54.72; H, 5.10; N, 5.00.

**Ethyl 2-phenyl-4-( $\beta$ -D-ribofuranosylthio)-6-methylpyrimidin-5-carboxylate (9a).** As for 7a; crystallized from ethanol to give colorless crystals; 85% yield; m.p. 148–150°C;  $R_f$  = 0.2 (eluent:  $\text{CH}_2\text{Cl}_2$ /MeOH; 9.6 : 0.4); IR (KBr)  $3381\text{ cm}^{-1}$  (broad, 3 OH),  $1704\text{ cm}^{-1}$  (CO, ester);  $^1\text{H}$  NMR spectrum (200 MHz, DMSO- $d_6$ /D $_2$ O)  $\delta$  1.41 (t, 3 H, J = 7.00 Hz,  $\text{CH}_3\text{CH}_2$ ), 2.64 (s, 3 H,  $\text{CH}_3$ -6), 3.50–3.60 (m, 2 H, H-5' and H-5''), 3.95 (m, 1 H, H-4'), 4.10 (dd, 1 H,  $J_{3',4'} = 4.8$ ,  $J_{2',3'} = 4.6\text{ Hz}$ , H-3'), 4.23 (dd, 1 H,  $J_{1',2'} = 3.83\text{ Hz}$ ,  $J_{2',3'} = 4.60\text{ Hz}$ , H-2'), 4.47 (q, 2 H, J = 7.00 Hz,  $\text{CH}_3\text{CH}_2$ ), 6.23 (d, 1 H,  $J_{1',2'} = 3.8\text{ Hz}$ , H-1'), 7.6–8.51 (m, 5H, Ar-H). Anal. Calcd for  $\text{C}_{19}\text{H}_{22}\text{N}_2\text{O}_6\text{S}$  (406.12): C, 56.15; H, 5.46; N, 6.89. Found: C, 55.90; H, 5.57; N, 6.72.

**Ethyl 2-(4-chlorophenyl)-4-( $\beta$ -D-ribofuranosylthio)-6-methylpyrimidin-5-carboxylate (9b).** As for 7a; crystallized from ethanol/water to give colorless crystals; 87% yield; m.p. 138–140°C;  $R_f$  = 0.38 (eluent:  $\text{CH}_2\text{Cl}_2$ /MeOH; 9.2 : 0.8); IR (KBr)  $3421\text{ cm}^{-1}$  (broad, 3 OH),  $1716\text{ cm}^{-1}$  (CO, ester);  $^1\text{H}$  NMR spectrum (300 MHz, DMSO- $d_6$ /D $_2$ O)  $\delta$  1.32 (t, 3 H, J = 7.2 Hz,  $\text{CH}_3\text{CH}_2$ ), 2.54 (s, 3 H,  $\text{CH}_3$ -6), 3.54 (m, 2 H, H-5' and H-5''), 3.86 (m, 1 H, H-4'), 4.00 (t, 1 H, J = 3.67 Hz, H-3'), 4.12 (t, 1 H, J = 3.6 Hz, H-2'), 4.36 (q, 2 H, J = 7.2 Hz,  $\text{CH}_3\text{CH}_2$ ), 6.12 (d, 1 H,  $J_{1',2'} = 3.6\text{ Hz}$ , H-1'), 7.59 (d, 2 H, J = 8.7 Hz, Ar-H) 8.43 (d, 2 H, J = 8.7 Hz, Ar-H);  $^{13}\text{C}$ -NMR (300 MHz, DMSO- $d_6$ )  $\delta$  20.6 and 20.7 (2  $\text{CH}_3$ ) 62.3 ( $\text{CH}_3\text{CH}_2$ ), 63.2 (C-5'), 73.0 (C-3'), 75.3 (C-2'), 75.8 (C-4'), 80.6 (C-1'), 116.0, 129.1, 131.0, 131.3, 134.0, 137.2, 169.0, 169.7 and 169.9 (Ar-C, 2 C=N and C=O). Anal. Calcd for  $\text{C}_{19}\text{H}_{21}\text{Cl N}_2\text{O}_6\text{S}$  (440.08): C, 51.76; H, 4.8; N, 6.53. Found: C, 51.77; H, 4.76; N, 6.38.

**Ethyl 2-(4-chlorophenyl)-4-( $\beta$ -D-ribofuranosyloxy)-6-methylpyrimidin-5-carboxylate (9c).** As for 7a; crystallized from ethanol/water to give colorless crystals; 86% yield; m.p. 115–117°C;  $R_f$  = 0.43 (eluent:  $\text{CH}_2\text{Cl}_2$ /MeOH; 9.2 : 0.8);  $^1\text{H}$  NMR spectrum (300 MHz, DMSO- $d_6$ )  $\delta$  1.32 (t, 3 H, J = 7.0 Hz,

CH<sub>3</sub>CH<sub>2</sub>), 2.49 (s, 3 H, CH<sub>3</sub>-6), 3.98–4.07 (m, 5 H, H-5', H-5'', H-4', H-3' and H-2'), 4.36 (q, 2 H, J = 7.0 Hz, CH<sub>3</sub>CH<sub>2</sub>), 4.2 (t, 1 H, J = 5.3 Hz, OH-5'), 4.26 (d, 1 H, J = 4.87 Hz, OH-3'), 4.3 (d, 1 H, J = 5.0 Hz, OH-2'), 6.03 (d, 1 H, J<sub>1',2'</sub> = 3.60 Hz, H-1'), 7.55 (d, 2 H, J = 8.90 Hz, Ar-H), 7.9 (d, 2 H, J = 8.90 Hz, Ar-H). Anal. Calcd for C<sub>19</sub>H<sub>21</sub>Cl N<sub>2</sub>O<sub>7</sub> (424.10): C, 53.72; H, 4.98; N, 6.59. Found: C, 53.54; H, 4.73; N, 6.60

## ANTIBACTERIAL SCREENING

The antimicrobial activities of some synthesized compounds were screened for their antibacterial activity against three species of bacteria, namely (*Pseudomonas aeruginosa*) as Gram (–ve), (*Staphylococcus aureus*), and (*Bacillus subtilis*) as Gram (+ve) using a cup agar diffusion method.<sup>[23]</sup> The tested compounds were dissolved in dimethyl sulfoxide to get a solution of 1 mg/mL concentration. The inhibition zone were measured in mm at the end of an incubation period of 48 hours at 37°C. Dimethyl sulfoxide showed no inhibition zones. Ampicillin was used as a reference.

## REFERENCES

1. Stawiniska, M.K.; Kaleta, K.; Sas, W.; DeClercq, E. Synthesis and antiviral properties of Aza-analogues of Acyclovir. *Nucleosides Nucleotides Nucleic Acid*. **2007**, 26, 51–64.
2. Khodair, A.I.; Ibrahim, E.E.; El Ashry, E.S.H. Glycosylation of 2-thiouracil derivatives. A synthetic approach to 3-glycosyl-2,4-dioxypyrimidines. *Nucleosides Nucleotides Nucleic Acids* **1997**, 16, 433–444.
3. Abdel-Rahman, A.A.H.; Abdel-Megied, A.E.S.; Goda, A.E.S.; El Ashry, E.S.H. Synthesis of anti-HBV activity of thiouracils linked via S and N-1 to the 5-position of methyl-D-ribofuranosid. *Nucleosides Nucleotides Nucleic Acids* **2003**, 22, 2027–2038.
4. Aly, A.A. A Convenient Synthesis and Pharmacological Activity of Novel Annelated Pyrimidine Derivatives. *J. Chin. Chem. Soc.* **2004**, 51, 1381–1388.
5. Johar, M.; Manning, T.; Kunimoto, D.Y.; Kumar, R. Synthesis and in vitro anti-mycobacterial activity of 5-substituted pyrimidine nucleosides. *Bioorg. Med. Chem. Lett.* **2005**, 13, 6663–6671.
6. Moustafa, A.H.; Saad, H.A.; Shehab, W.S.; El-Mobayed, M.M. Synthesis of some new pyrimidine derivatives of expected antimicrobial activity. *Phosphorus, Sulfur, Silicon* **2008**, 183, 115–135.
7. Ha, H.H.; Kim, J.S.; Kim, B.M. Novel heterocycle-substituted pyrimidines as inhibitors of NF-κB transcription regulation related to TNF-α cytokine release. *Bioorg. Med. Chem. Lett.* **2008**, 18, 653–656.
8. Díaz-Gavilán, M.; Gómez-Vidal, J.A.; Rodríguez-Serrano, F.; Marchal, J.A.; Caba, O.; Aránega, A.; Gallo, M.A.; Espinosa, A.; and Campos, J.M. Anticancer activity of (1,2,3,5-tetrahydro-4,1-benzoxazepine-3-yl)-pyrimidines and purines against the MCF-7 cell line: Preliminary cDNA microarray studies. *Bioorg. Med. Chem. Lett.* **2008**, 18, 1457–1460.
9. El-Ashry, E.S.H.; Rashed, N.; Abdel-Rahman, A.; Awad, L.F.; Rashed, H.A. Synthesis of 2-bromomethyl-3-hydroxy-2-hydroxymethylpropyl pyrimidine and theophyllin nucleosides under Microwave Irradiation. Evaluation of their activity against Hepatitis B Virus. *Nucleosides Nucleotides Nucleic Acids* **2006**, 25, 925–939.
10. Awad, O.M.E.; Attia, W.E.; El Ashry, E.S.H. Comparative evaluation of D-glucosyl thiuronium, glucosylthio heterocycles, Daonil, and insulin as inhibitors for hepatic glycosidases. *Carbohydr. Res.* **2004**, 339, 469–476.
11. El Ashry, E.S.H.; Rashed, N.; Shobier, A.H.S. Glycosidase inhibitors and their chemotherapeutic value. Part I. *Pharmazie* **2000**, 55, 251–262.

12. El Ashry, E.S.H.; Rashed, N.; Shobier, A.H.S. Glycosidase inhibitors and their chemotherapeutic value. Part 2. *Pharmazie* **2000**, 55, 331–348.
13. El Ashry, E.S.H.; Rashed, N.; Shobier, A.H.S. Glycosidase inhibitors and their chemotherapeutic value. Part 3. *Pharmazie* **2000**, 55, 403–415.
14. El Ashry, E.S.H.; El Nemr, A. *Synthesis of Naturally Occurring Nitrogen Heterocycles from Carbohydrates*; Blackwell: Oxford, UK, 2005.
15. Paul, B.; Korytnyk, W. S-,N-,and O-glycosyl derivatives of 2-acetamido-2-deoxy-D-glucose with hydrophobic aglycons as potent chemotherapeutic agents and N-acetyl- $\beta$ -D-glucosamidase inhibitors. *Carbohydr. Res.* **1984**, 126, 27–43.
16. Kuhn, C.S.; Lehmann, J.; Steck, J. Synthesis and properties of some photolabile  $\beta$ -thioglycosides. Potential photoaffinity reagent for  $\beta$ -glycoside hydrolase. *Tetrahedron* **1990**, 46, 3129–3134.
17. Blane-Muesser, M.; Vigne, L.; Driguez, H.; Lehmann, J.; Steck, J.; Urbhns, K. Spacer-modified disaccharide and pseudo-trisaccharid methyl glycosides that mimic maltotriose, as competitive inhibitors for ancreatic alpha-amylase: a dministration of the “clustering effect.” *Carbohydr. Res.* **1992**, 224, 59–71.
18. El Ashry, E.S.H.; Awad, L.F.; Atta, A.I. Synthesis and role of glycosylthio heterocycles in carbohydrate chemistry. *Tetrahedron*. **2006**, 62, 2943–2998.
19. Assy, M.G. Some reaction with ethyl 2-aryl-4-mercapto-6-methylpyrimidine-5-carboxylates. *Sulfur Lett.* **1990**, 11, 75–82.
20. Saad, H.A.; Moustafa, H.Y.; Assy, M.G.; Sayed, M.A. Functionalization and Hetero annelation of ethyl 2-(4-chlorophenyl)-4-mercapto-6-methylpyrimidine-5-carboxylate. *Bull. Korean Chem. Soc.* **2001**, 22, 311–314.
21. Andrzejewska, M.; Kaminski, J.; Kazimierczuk, Z. Microwave induced synthesis of riboncleosides on solid support. *Nucleosides Nucleotides Nucleic Acids* **2002**, 21, 73–78.
22. Mansour, A.K.; Eid, M.M.; Khalil, N.S.A.M. Synthesis of some new 2- $\alpha$ -L-arabinopyranosyl-1,2,4-triazines as potential antitumor chemotherapeutics. *Nucleosides Nucleotides Nucleic Acids* **2003**, 22, 1805–1823.
23. Haikal, A.Z.; El-Ashry, E.S.H.; Banoub, J. Synthesis and structural characterization of 1-(D-glycosyloxy)phthalazines. *Carbohydr. Res.* **2003**, 338, 2291–2299.
24. Reeves, D.S.; Hite, L.O. *Principles methods of assaying antibiotic in pharmaceutical microbiology*, Blackwell Scientific, Oxford, 1983. 3rd ed., p. 140.